Altamira Therapeutics Ltd.
CYTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | -0.01 | 0.23 |
| FCF Yield | 0.00% | -801.28% | -265.22% | -77.55% |
| EV / EBITDA | 0.00 | -0.68 | -0.59 | -3.20 |
| Quality | ||||
| ROIC | 0.00% | -85.68% | 3,055.40% | -37.25% |
| Gross Margin | 0.00% | 0.00% | -372.36% | -3,407.33% |
| Cash Conversion Ratio | 0.72 | 2.98 | 0.33 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | 20.54% | – | -48.35% |
| Free Cash Flow Growth | 45.99% | -6.33% | 36.31% | -137.45% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.38 | -0.36 | 0.06 |
| Interest Coverage | 0.00 | 0.00 | -19.76 | -378.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 124.01 | 2.67 |
| Cash Conversion Cycle | 0.00 | 0.00 | -217.84 | 3,891.50 |